00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
17:09 , Apr 23, 2019 |  BC Innovations  |  Distillery Therapeutics

The iron replacement drug Feraheme as a leukemia therapy

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Patient sample and mouse studies suggest Feraheme ferumoxytol could help treat AML with low ferroportin levels. In primary AML blasts and progenitor cells, levels of ferroportin were...
22:18 , Mar 13, 2019 |  BC Extra  |  Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

China's National Medical Insurance Administration released its plan for issuing a revised National Drug Reimbursement List Wednesday, describing which types of drugs will have priority for inclusion and sketching out a timeline for a revision...
17:31 , Mar 8, 2019 |  BC Week In Review  |  Company News

3SBio to market two Taiwan Liposome products in China

3SBio gained exclusive Chinese rights to commercialize two undisclosed liposomal products using Taiwan Liposome's NanoX platform in oncology and infectious disease indications. Taiwan Liposome Co. Ltd. (TPEx:4152; NASDAQ:TLC) and 3SBio Inc. (HKSE:1530) will together seek...
20:16 , Feb 21, 2019 |  BC Innovations  |  Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
18:14 , Feb 15, 2019 |  BC Week In Review  |  Company News

Samsung Bioepis partners with AffaMed, expands biosimilar development in China

Samsung Bioepis Co. Ltd. (Incheon, South Korea) partnered to develop four of its biosimilars with AffaMed Therapeutics (Shanghai, China). The partners will initially collaborate on clinical development, regulatory registration and commercialization Ontruzant, SB11, SB12 and...
23:26 , Feb 13, 2019 |  BC Week In Review  |  Company News

3SBio gains Verseau's macrophage checkpoint modulators for cancer

With a deal to license macrophage checkpoint modulators, 3SBio Inc. (HKSE:1530) is bypassing the standard roster of T cell targets and jumping to the next wave of immuno-oncology targets. The company is gaining exclusive access...
21:41 , Feb 11, 2019 |  BC Extra  |  Company News

3SBio gains Verseau's macrophage checkpoint modulators for cancer

With a deal to license macrophage checkpoint modulators, 3SBio Inc. (HKSE:1530) is bypassing the standard roster of T cell targets and jumping to the next wave of immuno-oncology targets. The company is gaining exclusive access...
01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
17:53 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regulatory reforms in China spark Samsung Bioepis deal with 3SBio

The regulatory reforms and growing China biopharma market has led South Korean company Samsung Bioepis Co. Ltd. (Incheon, South Korea) to expand its commercial reach via a deal with 3SBio Inc. (HKSE:1530). Samsung Bioepis said...